Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib + Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
NCT00499525Phase 2Unknown
- Sponsor
- Northwestern University
- Start
- Jun 2007
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sorafenib in breast cancer (2 arms), sponsored by Northwestern University. Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00499525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499525.